Clinical Trials Browser

belapectin × Clear all

NCT04987996 2023-06-06

GR-MD-02 + Pembrolizumab Versus Pembrolizumab Monotherapy in Melanoma and Squamous Cell Head and Neck Cancer Patients

Phase 2 Withdrawn

DermatologicHead & Neck

Squamous Cell Carcinoma of Head and Neck, Melanoma

NCT02575404 2023-06-05

GR-MD-02 Plus Pembrolizumab in Melanoma, Non-small Cell Lung Cancer, and Squamous Cell Head and Neck Cancer Patients

Phase 1 Completed

DermatologicHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Melanoma, Neoplasm Metastasis